Suggestions
Jeff Allen
President & CEO, Friends of Cancer Research
Jeff Allen is a highly accomplished professional with a strong educational background in Cell/Cellular and Molecular Biology. He completed his Doctor of Philosophy (Ph.D.) at Georgetown University School of Medicine and holds a Bachelor of Science (B.S.) in Biology from Bowling Green State University.
Throughout his career, Jeff Allen has had notable roles in prominent organizations. He served as the President & CEO of Friends of Cancer Research, where he played a vital role in advancing cancer research initiatives. Additionally, he worked as an Endocrinology & Immunology Research Fellow at The National Institutes of Health, showcasing his expertise in the field.
Highlights
NEW PUBLICATION - Results from our latest Real-World Evidence Pilot demonstrate how treatment response rate can be measured using real-world data.
Data obtained from clinical practice, or real-world data (#RWD), can provide valuable insights about treatment outcomes - particularly for patient populations not fully represented in prior clinical studies or for exploring potential other uses for new medicines. However, use of RWD as a research tool can require different methods and study considerations.
In our new study published in JCO CCI, we show that different sources of data can be used to implement a common approach and consistently evaluate response rates. This aligned method and reproducibility in results show that rwResponse can be a valuable metric to assess treatment effectiveness outside of traditional clinical trials.
Full publication: https://lnkd.in/diTaFg2Z RWE project page: https://lnkd.in/eEaJqjH9 Receive regular updates: https://lnkd.in/dCvFvkeX
Many thanks to our collaborators: American Society of Clinical Oncology (ASCO), ConcertAI, COTA, FDA, Flatiron Health, Friends of Cancer Research, Guardian Research Network, IQVIA, Memorial Sloan Kettering Cancer Center, Ontada, Syapse, Syneos Health, and Tempus AI
#RWEFriends #cancerresearch
Amazing opportunity to join The White House Clinical Trials Forum with leaders from The National Institutes of Health, National Cancer Institute (NCI), FDA, academic and clinical research, industry, and patient advocacy.
The forum brought together leaders to explore actions to make clinical research more accessible, inclusive, and efficient. The challenges are longstanding, but rapidly advancing capabilities for data capture and connectivity, infrastructure modernization, and patient engagement have opened doors for innovative policies toward progress.
As part of the forum, #FDA Commissioner Robert Califf released draft guidance on Diversity Action Plans established through the DEPICT Act: bit.ly/3L3g3Kg
Our recent publication demonstrates the growing commitment to provide additional data regarding racial and ethnic groups underrepresented in premarket clinical trials: bit.ly/4cl3RAh
For more information about Friends of Cancer Research projects aimed to accelerate the development of new medicines, please visit: https://lnkd.in/ejNGTdTK
Many thanks to Asal Sayas and Danielle Carnival, PhD for your continued leadership!
#clinicaltrials #cancer #research #policy
